Quantitative Assessment of Tumor Glucose Utilization for Prediction of Response to Treatment with the Epidermal Growth Factor Receptor Kinase Inhibitor Gefitinib (Iressa)
Restricted accessAbstractFirst published online January, 2006
Quantitative Assessment of Tumor Glucose Utilization for Prediction of Response to Treatment with the Epidermal Growth Factor Receptor Kinase Inhibitor Gefitinib (Iressa)